| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 因子XIIa形式 | CN200680007279.X | 2006-01-10 | CN101180391A | 2008-05-14 | 戴维·约翰·普里查德 |
| 一种53Kd的新形式的因子XIIa及相关产物，其包括核酸分子、单克隆和多克隆抗体、以及杂交瘤细胞株。本发明还包括53Kd形式的因子XIIa的测试方法，以及所述测试方法在诊断方法和预后性方法中的应用，例如用于心肌梗死主体存活率的预测。 | ||||||
| 2 | 抑制性的抗因子XII/XIIA单克隆抗体及其用途 | CN201280036288.7 | 2012-07-20 | CN103687878A | 2014-03-26 | C·帕努西斯; V·瑞兹曼; A·纳什; M·威尔逊; S·施密德鲍尔; M·诺尔蒂 |
| 本发明涉及抑制性抗因子XII/FXIIA抗体及其使用方法。 | ||||||
| 3 | 阻害性抗第ＸＩＩ／ＸＩＩＡ因子モノクローナル抗体及びそれらの使用 | JP2014520679 | 2012-07-20 | JP6253578B2 | 2017-12-27 | コン・パヌーシス; ヴェロニカ・レイズマン; アンドリュー・ナッシュ; マイケル・ウィルソン; シュテファン・シュミットバウアー; マルク・ノルテ |
| 4 | Forms of Factor XIIa | JP2007550834 | 2006-01-10 | JP2008526937A | 2008-07-24 | プリチャード，デイビッド，ジョン |
| 【課題】ファクターＸＩＩａ（“接触活性化系”の成分）及び新規なファクターＸＩＩａの分子量フォームを提供する。
【解決手段】本発明は、ファクターＸＩＩａの５３Ｋｄ新規フォーム及び核酸分子、モノクローナル及びポリクローナル抗体並びにハイブリドーマ細胞株を含む関連生成物に関するものである。 また、本発明は、ファクターＸＩＩａの５３Ｋｄフォームのための分析及び診断における前記分析の使用及び、例えば、心筋梗塞後の生存の予測における予測方法に関するものである。 【選択図】図６ |
||||||
| 5 | Methods of administering inhibitory anti-factor XII/XIIA monoclonal antibodies | US15343447 | 2016-11-04 | US09856326B2 | 2018-01-02 | Con Panousis; Veronika Rayzman; Andrew Nash; Michael Wilson; Stefan Schmidbauer; Marc Nolte |
| The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use. | ||||||
| 6 | Nucleic acids encoding inhibitory anti-factor XII/XIIa monoclonal antibodies | US15343401 | 2016-11-04 | US09856325B2 | 2018-01-02 | Con Panousis; Veronika Rayzman; Andrew Nash; Michael Wilson; Stefan Schmidbauer; Marc Nolte |
| The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use. | ||||||
| 7 | INHIBITORY ANTI-FACTOR XII/XIIA MONOCLONAL ANTIBODIES AND THEIR USES | US15343401 | 2016-11-04 | US20170121423A1 | 2017-05-04 | Con Panousis; Veronika Rayzman; Andrew Nash; Michael Wilson; Stefan Schmidbauer; Marc Nolte |
| The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use. | ||||||
| 8 | EPITOPE VACCINE FOR LOW IMMUNOGENIC PROTEIN AND PREPARING METHOD AND USAGE THEREOF | US14891351 | 2014-05-14 | US20160206732A1 | 2016-07-21 | Rongxiu LI; Li ZHANG; Conghao ZHONG; Chao CHENG; Aizhang XU; Wuguang LU; Zhibing Lin |
| The present invention provides recombinant protein carrying an epitope. The recombinant protein has a skeleton structure from carrier protein, and a low immunogenic protein epitope is imported through splicing, replacement, and/or insertion to at least one molecular surface amino acid residue area of the carrier protein. The carrier protein has at least one T cell epitope, and the recombinant protein can effectively excite immunoreaction of an organism to the low immunogenic protein epitope. | ||||||
| 9 | Forms of Factor Xiia | US11795074 | 2006-01-10 | US20080274477A1 | 2008-11-06 | David John Pritchard |
| A 53 Kd novel form of factor XIIa and related products, including nucleic acid molecules, monoclonal and polyclonal antibodies and hybridoma cell lines. Also assays for a 53 Kd form of factor XIIa and uses of said assays in diagnostic and prognostic methods, for example in the prediction of survival following myocardial infarction. | ||||||
| 10 | METHODS OF ADMINISTERING INHIBITORY ANTI-FACTOR XII/XIIA MONOCLONAL ANTIBODIES | US15822559 | 2017-11-27 | US20180134806A1 | 2018-05-17 | Con Panousis; Veronika Rayzman; Andrew Nash; Michael Wilson; Stefan Schmidbauer; Marc Nolte |
| The invention relates to inhibitory anti-factor XII/FXIla antibodies and methods of their use. | ||||||
| 11 | INHIBITORY ANTI-FACTOR XII/XIIA MONOCLONAL ANTIBODIES AND THEIR USES | US15343447 | 2016-11-04 | US20170137536A1 | 2017-05-18 | Con Panousis; Veronika Rayzman; Andrew Nash; Michael Wilson; Stefan Schmidbauer; Marc Nolte |
| The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use. | ||||||
| 12 | Inhibitory anti-factor XII/XIIA monoclonal antibodies and their uses | US14234021 | 2012-07-20 | US09518127B2 | 2016-12-13 | Con Panousis; Veronika Rayzman; Andrew Nash; Michael Wilson; Stefan Schmidbauer; Marc Nolte |
| The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use. | ||||||
| 13 | INHIBITORY ANTI-FACTOR XII/XIIA MONOCLONAL ANTIBODIES AND THEIR USES | US14234021 | 2012-07-20 | US20140199361A1 | 2014-07-17 | Con Panousis; Veronika Rayzman; Andrew Nash; Michael Wilson; Stefan Schmidbauer; Marc Nolte |
| The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use. | ||||||
| 14 | Abrogen polypeptides, nucleic acids encoding them and methods for using them to inhibit angiogenesis | US10424999 | 2003-04-29 | US20040052810A1 | 2004-03-18 | Mark Nesbit; Beatrice Cameron; Francis Blanche |
| The present invention relates to novel nucleic acids encoding novel amino acid fragments of polypeptides, called abrogens. The present invention also relates to novel, potent in vitro and in vivo inhibitors of endothelial cell proliferation, and compositions of them and their use. The present invention further provides methods for modulating angiogenesis and/or inhibiting unwanted angiogenesis. Polypeptides according to the present invention are useful for developing cell growth-modulating compositions and methods and for treating and/or preventing cancer, tumor growth, or other angiogenic dependent or angiogenesis associated diseases. | ||||||
| 15 | Kringle polypeptides and methods for using them to inhibit angiogenesis | US10425000 | 2003-04-29 | US20040052777A1 | 2004-03-18 | Mark Nesbit; Beatrice Cameron; Francis Blanche |
| The present invention relates to kringle polypeptides and polynucleotides encoding kringle polypeptides and their use as therapeutic agents and in methods of identifying agonist compounds. In effect, the kringle polypeptides according to the present invention are particularly useful for inhibiting in vitro and in vivo proliferation, migration and/or invasion of endothelial cells, recruitment of smooth muscle cells, and/or the formation of vasculature in a tissue. The present invention also relates to the use of kringle polypeptides for treating and/or preventing angiogenesis in tumors and inhibiting the growth of tumors. The present invention further relates to a method of modulating angiogenesis in cells affected by an angiogenic-dependent process and inhibiting unwanted or unregulated angiogenesis in an angiogenesis-associated disease. The present invention also concerns a method of production and purification of kringle polypeptides in a soluble and active form. | ||||||
| 16 | METHODS TO REDUCE ADVERSE EVENTS CAUSED BY PHARMACEUTICAL PREPARATIONS COMPRISING PLASMA DERIVED PROTEINS | EP12719993.3 | 2012-05-14 | EP2707005A1 | 2014-03-19 | SCHULTE, Stefan; KALINA, Uwe; MOSES, Michael; FEUSSNER, Annette |
| The instant invention provides a method to reduce adverse events caused by a pharmaceutical preparation derived from a plasma fraction said plasma fraction comprising antithrombin III wherein the method comprises contacting the plasma fraction with heparin or a heparin-like substance thereby reducing the activity of at least one activated serine protease per ml of the plasma fraction. | ||||||
| 17 | Inhibition of contact system activation | EP98202181.8 | 1998-06-29 | EP0982397A1 | 2000-03-01 | The designation of the inventor has not yet been filed |
Novel inhibitors of the contact system were developed by a) the discovery that the sequence encompassing the amino acid residues 39 to 47 of the heavy chain region of human FXII contributes to the binding of FXII to activators such as negatively charged surfaces; and b) the demonstration that peptides mimicking this identified sequence inhibit the binding of FXII to activators and prevent contact system activation in human plasma. These novel contact system inhibitors may be applied to prevent activation of the contact system of blood by artificial surfaces, or used as anti-inflammatory drug for the prophylactic or therapeutic treatment of human or animal diseases. |
||||||
| 18 | MONOCLONAL ANTIBODIES TO THE LIGHT CHAIN REGION OF HUMAN FACTOR XII AND METHODS OF PREPARING AND USING THE SAME | EP89907964.0 | 1989-05-26 | EP0419574A1 | 1991-04-03 | PIXLEY, Robin, A.; COLMAN, Robert, W. |
| De nouvelles lignées cellulaires hybrides produisent des anticorps monoclonaux contre la région à chaîne légère du facteur human XII. Trois de ces lignées cellulaires, ADCC #HB-9703, à ATCC #HB-9704, sont formées par fusion de cellules de myélome SP2/0-Ag14 avec des cellules de la rate provenant de souris BALB/c AnSkh immunisées avec le facteur humain XIIf. Les anticorps monoclonaux peuvent être utilisés par exemple pour éliminer des fragments de facteur humain XII contenant la chaîne légère du facteur XII, qui se trouve dans des liquides, par exemple des produits de plasma sanguin. | ||||||
| 19 | ADENO-ASSOCIATED VIRUS MEDIATED DELIVERY OF C1EI AS A THERAPY FOR ANGIOEDEMA | US15167729 | 2016-05-27 | US20160347822A1 | 2016-12-01 | Ronald G. Crystal; Odelya E. Pagovich; Maria J. Chiuchiolo |
| This invention is directed to a vector which comprises a promoter operably linked to a nucleic acid sequence encoding the human C1 esterase inhibitor or Factor XII. The invention is also directed to a composition comprising the vector and a method of using the vector to treat or prevent hereditary angioedema. | ||||||
| 20 | ASSAYS FOR DETERMINING PLASMA KALLIKREIN SYSTEM BIOMARKERS | US15030811 | 2014-10-17 | US20160252527A1 | 2016-09-01 | Daniel J. Sexton; Ryan Faucette; Jon A. Kenniston; Gregory P. Conley; Andrew Nixon; Christopher TenHoor; Burt Adelman |
| Methods and assays for determining the activation level of the plasma kallikrein (pKal) system and the uses thereof for assessing the activity of pKal modulators on the pKal system. | ||||||
QQ群二维码
意见反馈
意见反馈